aptaTargets’ ApTOLL reduces mortality from 18% to 5% in a Phase 1b/2a trial in ischemic st... 09/02/2023 Healthcare Corporate ApTOLL is the first TLR4 antagonist neuroprotectant to achieve positive efficacy endpoints in acute ischemic stroke... Partners - AptaTargets
BCN HEALTH publishes a study assessing the incidence, mortality and hospital costs of isch... 30/01/2023 Healthcare Corporate BCN HEALTH ha publicado el estudio 'Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs... Partners - BCN Health
GENESIS Biomed sponsors ITEMAS 2022 Annual Conference Day 19/01/2023 Corporate The “Instituto de Investigación Biomédica de Córdoba” hosts the event, supported by “Instituto de Salud Carlos III... Partners - GENESIS Biomed
AptaTargets awarded €2.5 million grant from Spanish government to evaluate ApTOLL for acut... 23/01/2023 Healthcare Access to innovation Corporate The funds are from a competitive call through the 2021 State Programme to Promote Scientific-Technical Research and its... Partners - AptaTargets
Cellab CDMO, Cellab's new activity 19/01/2023 Corporate The Andorran biotech company is working to obtain Good Manufacturing Practices (GMP) during the first half of 2023 Partners - Cellab
Ysios Capital strengthens its team with internal promotions and a new Venture Partner 19/01/2023 Access to innovation Corporate Jordi Xiol has been promoted to Partner after joining Ysios Capital in 2019 Ysios is also incorporating Sanifit co... Partners - Ysios Capital Partners
BCN HEALTH has published 10 studies in 2022 assessing the incidence and costs of illness o... 19/01/2023 Healthcare Access to innovation Corporate BCN HEALTH has published 10 studies in 2022 assessing the incidence and cost of illness of different diseases in Spain. Partners - BCN Health
DIVERSA Technologies is driven by Innovation 19/01/2023 Access to innovation Corporate The Galician Innovation Agency has awarded DIVERSA through the InnovaPeme program to implement its innovation plan in... Partners - DIVERSA Technologies
The first orally administered biologic medicine based on intestinal microbiota: fiction or... 18/01/2023 Healthcare Access to innovation Corporate Mikrobiomik aims to be the first company in the world to commercialize the first biologic medicine based on intestinal... Partners - Mikrobiomik
La biotech española Laminar Pharma alcanza la cifra de 45 pacientes reclutados en el ensay... 18/01/2023 Healthcare Corporate Laminar Pharmaceuticals S.A., se complace en anunciar el reclutamiento de los primeros 45 pacientes en el estudio... Partners - Laminar Pharma
